Peter F. Lebowitz

Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations

Keith T. Flaherty, J. Infante, Adil Daud et al. · New England Journal of Medicine · 2012 · 2.8K citations · Full text

Medicine, Oncology, Pharmacology +16

Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial

Gerald S. Falchook, Georgina V. Long, Razelle Kurzrock et al. · The Lancet · 2012 · 933 citations · Full text

Medicine, Oncology, Pharmacotherapy +12

Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial

Gerald S. Falchook, Karl D. Lewis, Jeffrey R. Infante et al. · The Lancet Oncology · 2012 · 542 citations · Full text

Medicine, Oncology, Pharmacology +17

Phase I/II study of GSK2118436, a selective inhibitor of oncogenic mutant BRAF kinase, in patients with metastatic melanoma and other solid tumors.

Richard Kefford, Hendrik‐Tobias Arkenau, Michael P. Brown et al. · Journal of Clinical Oncology · 2010 · 274 citations

Medicine, Oncology, Pharmacology +17

Critical role of Rho in cell transformation by oncogenic Ras.

George C. Prendergast, Roya Khosravi‐Far, Patricia A. Solski et al. · PubMed · 1995 · 253 citations

Medicine, Cancer Biology, Cell Biology +16